<p>Enanta Pharmaceuticals, Inc.（纳斯达克代码：ENTA - 获取免费报告）内部人士 Tara Lynn Kieffer 于 12 月 5 日（星期五）出售了 2,106 股该公司的股票。股票的平均售价为 14.23 美元，总价值为 29,968.38 美元。出售完成后，该内部人士持有 30,620 股公司股票，价值为 435,722.60 美元。此次交易使其持股减少了 6.44%。该出售在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此链接获取。</p>
<p>获取 <strong>Enanta Pharmaceuticals</strong> 的提醒：</p>
<h2>Enanta Pharmaceuticals 股价上涨 3.6%</h2>
<p>Enanta Pharmaceuticals 股票在周五交易中上涨了 0.51 美元，达到 14.60 美元。该股票的交易量为 333,749 股，而其平均交易量为 400,542 股。该股票的 50 日简单移动平均为 11.89 美元，200 日简单移动平均为 9.04 美元。该公司的市值为 4.2136 亿美元，市盈率为-3.81，贝塔值为 0.96。Enanta Pharmaceuticals, Inc. 的 52 周最低价为 4.09 美元，最高价为 15.34 美元。</p>
<p>Enanta Pharmaceuticals（纳斯达克代码：ENTA - 获取免费报告）最近于 11 月 17 日（星期一）发布了季度财报。这家生物技术公司报告本季度每股收益（EPS）为-0.87 美元，超出分析师一致预期的-1.13 美元，超出幅度为 0.26 美元。该公司本季度的收入为 1513 万美元，而一致预期为 1560 万美元。Enanta Pharmaceuticals 的净利润率为-125.36%，股本回报率为-93.76%。整体来看，股票分析师预计 Enanta Pharmaceuticals, Inc. 本年度将发布-4.65 的每股收益。</p>
<h2>机构投资者对 Enanta Pharmaceuticals 的看法</h2>
<p>大型投资者最近买入和卖出了该公司的股票。俄亥俄州公共雇员退休系统在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 8.3%。该系统目前持有 14,412 股生物技术公司的股票，价值 173,000 美元，此前在上个季度又购买了 1,100 股。Ameriprise Financial Inc.在第三季度将其在 Enanta Pharmaceuticals 的股份增加了 8.3%。Ameriprise Financial Inc.目前持有 18,007 股生物技术公司的股票，价值 216,000 美元，此前在该期间又收购了 1,383 股。AlphaQuest LLC 在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 18.1%。AlphaQuest LLC 目前持有 10,198 股生物技术公司的股票，价值 122,000 美元，此前在上个季度又购买了 1,562 股。Sio Capital Management LLC 在第二季度将其在 Enanta Pharmaceuticals 的持股增加了 1.0%。Sio Capital Management LLC 目前持有 178,774 股生物技术公司的股票，价值 1,352,000 美元，此前在上个季度又购买了 1,770 股。最后，Russell Investments Group Ltd.在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 13.4%。Russell Investments Group Ltd.目前持有 16,443 股生物技术公司的股票，价值 197,000 美元，此前在该期间又购买了 1,940 股。对冲基金和其他机构投资者持有该公司 94.99% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司最近对 ENTA 发表了评论。Evercore ISI 在 9 月 15 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 20.00 美元下调至 12.00 美元，并对该公司给予了 “跑赢大盘” 的评级。Jefferies Financial Group 在 10 月 1 日的研究报告中将 Enanta Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将该股票的目标价格从 14.00 美元上调至 20.00 美元。摩根大通在 11 月 14 日的研究报告中开始覆盖 Enanta Pharmaceuticals，给予 “增持” 评级，目标价格为 17.00 美元。JMP Securities 在 8 月 12 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 24.00 美元上调至 25.00 美元，并给予该股票 “市场跑赢” 的评级。最后，Westpark Capital 在 9 月 30 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 20.33 美元。</p>
<p><strong>查看我们关于 ENTA 的最新报告</strong></p>
<h2>Enanta Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Enanta Pharmaceuticals, Inc.是一家生物技术公司，专注于发现和开发用于治疗病毒感染和肝脏疾病的小分子药物。其产品管线包括 EDP-514，目前正在进行针对慢性乙型肝炎病毒（HBV）感染的 1b 期临床开发；EDP-938 和 EDP-323，目前正在进行针对呼吸道合胞病毒的 II 期临床开发；EDP-235，目前正在进行针对人类冠状病毒的 II 期临床开发；以及 Glecaprevir，目前已上市用于治疗慢性丙型肝炎病毒（HCV）感染。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Enanta Pharmaceuticals 更具吸引力</li>
<li>如何开始投资房地产</li>
<li>Rocket Lab 的强劲反弹？分析师认为此次下跌是个机会</li>
<li>投资者如何从盘后交易中获益</li>
<li>Meta 的人工智能时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Enanta 制药吗？</h2>
<p>在你考虑 Enanta 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enanta 制药并不在名单上。</p>
<p>虽然 Enanta 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Enanta制药

<p>Enanta 制药的内部人士 Tara Lynn Kieffer 出售了 2,106 股，每股价格为 14.23 美元，总计 29,968.38 美元。交易后，她持有 30,620 股，持股比例下降了 6.44%。此次出售已向美国证券交易委员会（SEC）披露。Enanta 的股票上涨了 3.6%，达到 14.60 美元，市值为 4.2136 亿美元。分析师的评级不一，有些分析师提高了目标价格。机构投资者持有 94.99% 的股票</p>

<p>Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) insider Tara Lynn Kieffer sold 2,106 shares of the business's stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider owned 30,620 shares of the company's stock, valued at $435,722.60. The trade was a 6.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Enanta Pharmaceuticals, Inc.（纳斯达克代码：ENTA - 获取免费报告）内部人士 Tara Lynn Kieffer 于 12 月 5 日（星期五）出售了 2,106 股该公司的股票。股票的平均售价为 14.23 美元，总价值为 29,968.38 美元。出售完成后，该内部人士持有 30,620 股公司股票，价值为 435,722.60 美元。此次交易使其持股减少了 6.44%。该出售在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Get <strong>Enanta Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Enanta Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Enanta Pharmaceuticals Trading Up 3.6%</h2>
<div class="lb-trans"><h2>Enanta Pharmaceuticals 股价上涨 3.6%</h2>
</div><p>Shares of Enanta Pharmaceuticals stock traded up $0.51 during trading on Friday, hitting $14.60. 333,749 shares of the stock traded hands, compared to its average volume of 400,542. The stock's fifty day simple moving average is $11.89 and its 200 day simple moving average is $9.04. The firm has a market cap of $421.36 million, a P/E ratio of -3.81 and a beta of 0.96. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.09 and a 52-week high of $15.34.</p>
<div class="lb-trans"><p>Enanta Pharmaceuticals 股票在周五交易中上涨了 0.51 美元，达到 14.60 美元。该股票的交易量为 333,749 股，而其平均交易量为 400,542 股。该股票的 50 日简单移动平均为 11.89 美元，200 日简单移动平均为 9.04 美元。该公司的市值为 4.2136 亿美元，市盈率为-3.81，贝塔值为 0.96。Enanta Pharmaceuticals, Inc. 的 52 周最低价为 4.09 美元，最高价为 15.34 美元。</p>
</div><p>Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.26. The firm had revenue of $15.13 million for the quarter, compared to the consensus estimate of $15.60 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. As a group, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.</p>
<div class="lb-trans"><p>Enanta Pharmaceuticals（纳斯达克代码：ENTA - 获取免费报告）最近于 11 月 17 日（星期一）发布了季度财报。这家生物技术公司报告本季度每股收益（EPS）为-0.87 美元，超出分析师一致预期的-1.13 美元，超出幅度为 0.26 美元。该公司本季度的收入为 1513 万美元，而一致预期为 1560 万美元。Enanta Pharmaceuticals 的净利润率为-125.36%，股本回报率为-93.76%。整体来看，股票分析师预计 Enanta Pharmaceuticals, Inc. 本年度将发布-4.65 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Enanta Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Enanta Pharmaceuticals 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its position in Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company's stock worth $173,000 after buying an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company's stock worth $216,000 after acquiring an additional 1,383 shares during the period. AlphaQuest LLC raised its holdings in shares of Enanta Pharmaceuticals by 18.1% during the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 1,562 shares during the last quarter. Sio Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 1.0% during the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company's stock worth $1,352,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Enanta Pharmaceuticals by 13.4% during the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company's stock valued at $197,000 after purchasing an additional 1,940 shares during the period. Hedge funds and other institutional investors own 94.99% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。俄亥俄州公共雇员退休系统在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 8.3%。该系统目前持有 14,412 股生物技术公司的股票，价值 173,000 美元，此前在上个季度又购买了 1,100 股。Ameriprise Financial Inc.在第三季度将其在 Enanta Pharmaceuticals 的股份增加了 8.3%。Ameriprise Financial Inc.目前持有 18,007 股生物技术公司的股票，价值 216,000 美元，此前在该期间又收购了 1,383 股。AlphaQuest LLC 在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 18.1%。AlphaQuest LLC 目前持有 10,198 股生物技术公司的股票，价值 122,000 美元，此前在上个季度又购买了 1,562 股。Sio Capital Management LLC 在第二季度将其在 Enanta Pharmaceuticals 的持股增加了 1.0%。Sio Capital Management LLC 目前持有 178,774 股生物技术公司的股票，价值 1,352,000 美元，此前在上个季度又购买了 1,770 股。最后，Russell Investments Group Ltd.在第三季度将其在 Enanta Pharmaceuticals 的持股增加了 13.4%。Russell Investments Group Ltd.目前持有 16,443 股生物技术公司的股票，价值 197,000 美元，此前在该期间又购买了 1,940 股。对冲基金和其他机构投资者持有该公司 94.99% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms recently commented on ENTA. Evercore ISI decreased their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an &#34;outperform&#34; rating for the company in a research report on Monday, September 15th. Jefferies Financial Group raised Enanta Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating and upped their price target for the stock from $14.00 to $20.00 in a research report on Wednesday, October 1st. JPMorgan Chase &amp; Co. began coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an &#34;overweight&#34; rating and a $17.00 price objective for the company. JMP Securities boosted their target price on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Tuesday, August 12th. Finally, Westpark Capital increased their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, September 30th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average target price of $20.33.</p>
<div class="lb-trans"><p>多家研究公司最近对 ENTA 发表了评论。Evercore ISI 在 9 月 15 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 20.00 美元下调至 12.00 美元，并对该公司给予了 “跑赢大盘” 的评级。Jefferies Financial Group 在 10 月 1 日的研究报告中将 Enanta Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将该股票的目标价格从 14.00 美元上调至 20.00 美元。摩根大通在 11 月 14 日的研究报告中开始覆盖 Enanta Pharmaceuticals，给予 “增持” 评级，目标价格为 17.00 美元。JMP Securities 在 8 月 12 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 24.00 美元上调至 25.00 美元，并给予该股票 “市场跑赢” 的评级。最后，Westpark Capital 在 9 月 30 日的研究报告中将 Enanta Pharmaceuticals 的目标价格从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 20.33 美元。</p>
</div><p><strong>View Our Latest Report on ENTA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ENTA 的最新报告</strong></p>
</div><h2>Enanta Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Enanta Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.</p>
<div class="lb-trans"><p>Enanta Pharmaceuticals, Inc.是一家生物技术公司，专注于发现和开发用于治疗病毒感染和肝脏疾病的小分子药物。其产品管线包括 EDP-514，目前正在进行针对慢性乙型肝炎病毒（HBV）感染的 1b 期临床开发；EDP-938 和 EDP-323，目前正在进行针对呼吸道合胞病毒的 II 期临床开发；EDP-235，目前正在进行针对人类冠状病毒的 II 期临床开发；以及 Glecaprevir，目前已上市用于治疗慢性丙型肝炎病毒（HCV）感染。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Enanta Pharmaceuticals</li>
<li>How to Start Investing in Real Estate</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Enanta Pharmaceuticals 更具吸引力</li>
<li>如何开始投资房地产</li>
<li>Rocket Lab 的强劲反弹？分析师认为此次下跌是个机会</li>
<li>投资者如何从盘后交易中获益</li>
<li>Meta 的人工智能时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ENTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Enanta 制药吗？</h2>
</div><p>Before you consider Enanta Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Enanta 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enanta 制药并不在名单上。</p>
</div><p>While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enanta 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tara Lynn Kieffer 出售了 2,106 股 Enanta 制药（NASDAQ:ENTA）的股票